At the recent Cell and Gene Therapy Conference, DDD spoke with the Dr Stefan Chabierski, from ASKION about how evolving demands in the cell and gene therapy sector are shaping the need for more advanced biobanking and cryogenic storage solutions.
The discussion highlighted the pressures facing developers as therapies move from research into clinical and commercial stages, where safeguarding biological samples, ensuring traceability, and managing increasingly complex workflows are critical.
Managing High-Value Biological Samples As advanced therapies scale, the safe storage and handling of sensitive cell materials is becoming increasingly important.
Technologies that support reliable cryogenic storage, automated handling, and robust sample management infrastructure are helping organisations maintain sample integrity while navigating the logistical challenges associated with growing clinical pipelines.
Workforce Challenges and the Role of Automation
At the same time, the industry is navigating workforce constraints, making automation and smarter laboratory infrastructure increasingly important for supporting teams responsible for handling high-value biological materials.
Reducing manual intervention can help improve consistency while enabling labs to operate more efficiently as demand grows.
AI and Data-Driven Biobanking
The growing influence of Artificial Intelligence and digital technologies is also reshaping how organisations manage biological samples and associated data.
AI-driven tools are helping optimise workflows, improve traceability, and support data-driven decision-making across the cell and gene therapy landscape.
Scaling the Next Generation of Therapies
Together, these trends are shaping how companies scale operations while maintaining quality and consistency across the cell and gene therapy pipeline.
